FOR IMMEDIATE RELEASE: Web-Based Certification Program Helps Drug Test Administrators KINDERHOOK, N.Y. -- Sept. 25, 2002 -- American Bio Medica Corporation (NASDAQ: ABMC) today announced the launch of a progressive online training and certification course designed specifically to help drug testing program administrators further their understanding of ABMC's products. Training and certification related to the Company's Rapid Drug Screen® and Rapid One® drug tests is currently available, while training and certification for the Company's OralStat6® and Rapid Tec series is expected to be available in the near future. The company introduced the project as a service to its customers, and as a result of growing acceptance and use of its on-site drug tests. The course can be accessed at www.abmc.com/training. Users are asked to register and create a password, which allows anytime access to the training information. The course provides educational information on the products and their applications, and also an online examination. Those who pass the examination receive a manufacturer's certification. "With the growing acceptance and use of our products we received requests from customers for more readily-accessible information relative to product training," noted ABMC chairman and CEO Gerald Moore. "Because our products are very easy to use, we can leverage our web site to supplement the efforts of ABMC's sales, technical and customer service staff. It is another example of ABMC going an extra step in responding to the needs of the customer." About American Bio Medica Corporation American Bio Medica Corporation is a biotechnology company that develops, manufactures and markets inexpensive, accurate, immunoassay diagnostic test kits, including some of the world's most effective on-site drugs of abuse tests. The company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC's Rapid Drug Screen, Rapid One, and Rapid Tec test for the presence or absence of drugs of abuse in urine, while OralStat6 tests for the presence or absence of drugs of abuse in saliva. ABMC was recently listed among the top ten biotechnology companies on the Deloitte & Touche 2001 Technology Fast 500, a ranking of the fastest growing companies in North America. This release may contain forward-looking statements. These
forward-looking statements involve risks and uncertainties that could
cause actual results to differ, and such differences could be
material. Such risks and uncertainties include, but are not limited
to, the following: continued acceptance of the Company's products,
increased levels of competition in our industry, the acceptance of new
products, inherent risks associated with product development and
intellectual property rights, the Company's dependence on key
personnel, third party sales and suppliers. There can be no assurance
that the Company will be successful in addressing such risks and
uncertainties. Investors are strongly encouraged to review the section
entitled "Risk Factors" in the Company's annual report on Form 10-KSB
for the transition period ended December 31, 2001, and quarterly
reports on Form 10-QSB on file with the Securities and Exchange
Commission for a discussion of risks and uncertainties that could
affect operating results and the market price of the Company's common
shares.
Contact: American Bio Medica Corporation Gerald A. Moore, 800/227-1243 Fax: 518/758-8171 gerald@americanbiomedica.com www.americanbiomedica.com
|